Evidence map›Paper›PMID 28824054›Full record

ArticleInternal medicine (Tokyo, Japan)2017

Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.

Kiyoe Kurahashi, Itsuro Endo, Takeshi Kondo, Kana Morimoto, Sumiko Yoshida, Akio Kuroda, Ken-Ichi Aihara, Munehide Matsuhisa, Kohei Nakajima, Yoshifumi Mizobuchi and 3 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Kiyoe KurahashiDepartment of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan.
Itsuro EndoDepartment of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan.
Takeshi KondoDepartment of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan.
Kana MorimotoDepartment of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan.
Sumiko YoshidaDepartment of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan.
Akio KurodaDiabetes Therapeutics and Research Center, Tokushima University, Japan.
Ken-Ichi AiharaDepartment of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan.
Munehide MatsuhisaDiabetes Therapeutics and Research Center, Tokushima University, Japan.
Kohei NakajimaDepartment of Neurosurgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan.
Yoshifumi MizobuchiDepartment of Neurosurgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan.
Shinji NagahiroDepartment of Neurosurgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan.
Masahiro AbeDepartment of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan.
Seiji FukumotoInstitute of Advanced Medical Sciences, Fujii Memorial Institute of Medical Sciences, Tokushima University, Japan.
Tokushima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acromegaly is caused by excessive growth hormone secretion, usually from pituitary adenomas. Somoatostatin analogues are widely used as primary or adjunctive therapy in the management of acromegaly. In this report, we present a case with remarkable shrinkage of a tumor after relatively short-term octreotide long-acting release (LAR) administration. During the 30-month follow-up after starting octreotide LAR, there was no recurrence of acromegaly with remarkable shrinkage of the tumor on pituitary magnetic resonance imaging. A literature review of the predictors for tumor shrinkage after the administration of somatostatin analogues in patients with acromegaly is also discussed in relation to this case.

Indexed as

AcromegalyAdenomaAntineoplastic Agents, HormonalGrowth HormoneHumansMagnetic Resonance ImagingMaleMiddle AgedOctreotidePituitary NeoplasmsSomatostatinAntineoplastic Agents, HormonalGrowth HormoneOctreotideSomatostatinGH-secreting macroadenomaremarkable shrinkagesomatostatin analogue

Identifiers

PMID28824054
PMCPMC5643174
OpenAlexW2747666184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.